Artificial intelligence to revolutionize IBD clinical trials: a comprehensive review

Area of Science:

• Clinical research
• Artificial intelligence in medicine
• Inflammatory Bowel Disease (IBD) therapeutics

Background:

• Inflammatory Bowel Disease (IBD) clinical trials face challenges in efficiency, accuracy, and personalization.
• Artificial intelligence (AI) offers transformative potential for enhancing IBD research.

Purpose of the Study:

• To explore the application of AI-driven technologies in IBD clinical trials.
• To identify how AI can improve patient recruitment, trial design, data analysis, and personalized treatment strategies.
• To discuss the challenges and necessary steps for successful AI integration in IBD trials.

Main Methods:

• Review of AI technologies including machine learning (ML), natural language processing, and predictive analytics.
• Integration of multi-omics data, electronic health records, and imaging data.
• Analysis of AI's role in streamlining trial phases from target identification to patient monitoring.

Main Results:

• AI can enhance IBD trial efficiency, accuracy, and personalization, accelerating novel therapy discovery.
• AI facilitates streamlining trial processes, uncovering molecular targets, and personalizing strategies.
• Significant challenges include data integration, patient privacy, regulatory standards, and potential AI bias due to lack of diverse datasets.

Conclusions:

• Overcoming technical, ethical, and regulatory hurdles is crucial for AI adoption in IBD trials.
• Standardized data, interdisciplinary collaboration, and ethical frameworks are essential for inclusive and accurate AI implementation.
• AI holds significant potential to improve the efficiency, equity, and efficacy of IBD clinical trials, ultimately benefiting patient care.